BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lorlatinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lorlatinib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05059522-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lorlatinib: Phase 3 readout est. (NCT05059522)
DESCRIPTION:Lorlatinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cont
 inued Access Study for Participants Deriving Benefit in Pfizer-Sponsored A
 velumab Parent Studies That Are Closing\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lorlat
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05059522
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07083687-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Lorlatinib: Phase 2 readout est. (NCT07083687)
DESCRIPTION:Lorlatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Lorl
 atinib in ROS1+ NSCLC With Brain Metastasis\nEstimated primary completion:
  1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lorl
 atinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07083687
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06893354-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270720
DTEND;VALUE=DATE:20270721
SUMMARY:Lorlatinib: Phase 4 readout est. (NCT06893354)
DESCRIPTION:Lorlatinib\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: Expl
 ore the Mechanisms Underlying Disease Resistance and Potential Primary Res
 istance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small 
 Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Singl
 e-cell RNA Sequencing and Spatial Transcriptomics\nEstimated primary compl
 etion: 20 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 lorlatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06893354
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784959-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lorlatinib: Phase 1 readout est. (NCT07784959)
DESCRIPTION:Lorlatinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of NXP900 With Lorlatinib in ALK+ Lung Cancer\nEstimated primary complet
 ion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lor
 latinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07784959
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Lorlatinib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Lorlatinib\, phase 2.\nStudy: The Drug Rediscovery Protocol (DR
 UP Trial)\nEstimated primary completion: September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/lorlatinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938463-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Lorlatinib: Phase 1 readout est. (NCT07938463)
DESCRIPTION:Lorlatinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Lorl
 atinib Plus TNG462 in ALK+ MTAP Del NSCLC\nEstimated primary completion: 3
 0 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lorl
 atinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07938463
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06378892-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Lorlatinib: Phase 2 readout est. (NCT06378892)
DESCRIPTION:Lorlatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy 
 Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Ex
 clusively Extracranial Disease Progression on Lorlatinib\nEstimated primar
 y completion: May 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/lorlatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06378892
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415005-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280722
DTEND;VALUE=DATE:20280723
SUMMARY:Lorlatinib: Phase 2 readout est. (NCT07415005)
DESCRIPTION:Lorlatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Lorl
 atinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small
  Cell Lung Cancer\nEstimated primary completion: 22 July 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/lorlatinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07415005
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06007937-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:Lorlatinib: Phase 1/2 readout est. (NCT06007937)
DESCRIPTION:Lorlatinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Lorlatinib in Combination With Ramucirumab in People With Lung Ca
 ncer\nEstimated primary completion: 17 August 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lorlatinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06007937
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06487078-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Lorlatinib: Phase na readout est. (NCT06487078)
DESCRIPTION:Lorlatinib\, phase na\, Non-Small Cell Lung Cancer.\nStudy: Ana
 lysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Posit
 ive NSCLC Patients in a French Real-World Context\nEstimated primary compl
 etion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/lorlatinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06487078
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06333899-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Lorlatinib: Phase 1 readout est. (NCT06333899)
DESCRIPTION:Lorlatinib\, phase 1.\nStudy: Lorlatinib for Newly-Diagnosed Hi
 gh-Grade Glioma With ROS or ALK Fusion\nEstimated primary completion: 1 Ju
 ly 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/lorlatinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06333
 899
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750704-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Lorlatinib: Phase 2 readout est. (NCT07750704)
DESCRIPTION:Lorlatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Lorl
 atinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as Firs
 t-Line Therapy for ALK Fusion-Positive NSCLC\nEstimated primary completion
 : September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lor
 latinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07750704
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05144997-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20291025
DTEND;VALUE=DATE:20291026
SUMMARY:Lorlatinib: Phase 4 readout est. (NCT05144997)
DESCRIPTION:Lorlatinib\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: Lorl
 atinib Continuation Study\nEstimated primary completion: 25 October 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lorlatinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05144997
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858410-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Lorlatinib: Phase 3 readout est. (NCT06858410)
DESCRIPTION:Lorlatinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Lorl
 atinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III
  ALK Positive Lung Adenocarcinoma\nEstimated primary completion: March 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/lorlatinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06858410
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07617337-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Lorlatinib: Phase 1 readout est. (NCT07617337)
DESCRIPTION:Lorlatinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: AQUA
 07 in Patients With ALK-Positive Non-Small Cell Lung Cancer\nEstimated pri
 mary completion: 31 August 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/lorlatinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07617337
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03126916-1970@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Lorlatinib: Phase 3 readout est. (NCT03126916)
DESCRIPTION:Lorlatinib\, phase 3.\nStudy: Testing the Addition of 131I-MIBG
  or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma
  (NBL)\nEstimated primary completion: 30 September 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/lorlatinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03126916
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
